Stockscreener 앱 받기
0.8584
6.20%
-0.0567
시간 외 거래:
.84
-0.0184
-2.14%
전일 마감가:
$0.9151
열려 있는:
$0.95
하루 거래량:
986.62K
Relative Volume:
0.87
시가총액:
$83.61M
수익:
-
순이익/손실:
$-20.31M
주가수익비율:
-3.2454
EPS:
-0.2645
순현금흐름:
$-21.07M
1주 성능:
-13.29%
1개월 성능:
-31.33%
6개월 성능:
+10.48%
1년 성능:
-12.91%
1일 변동 폭
$0.83
$0.95
1주일 범위
$0.80
$1.01
52주 변동 폭
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.8584 | 89.84M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Advances Pelareorep with Strategic Moves - MSN
Oncolytics Biotech: A High-Conviction Play in the Next-Gen Immunotherapy Space - AInvest
Oncolytics Biotech Advances Pelareorep Clinical Program with Strategic Moves - The Globe and Mail
Oncolytics Biotech Reports Reduced Losses in Q2 2025 Financial Update - The Globe and Mail
(ONC) Strategic Market Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange - The Malaysian Reserve
Oncolytics Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oncolytics Biotech to Delist from TSX, Focus on Nasdaq - TipRanks
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried? - The Globe and Mail
Oncolytics Biotech's Q2 Loss Narrows: A Strategic Turnaround or a Fleeting Reprieve? - AInvest
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Q2 net loss narrows - MarketScreener
Oncolytics Biotech Files SEC Report Incorporating Information Circular - TipRanks
Oncolytics Biotech reports Q2 highlights, management team updates, and financial results. - AInvest
Oncolytics Biotech to delist from Toronto Stock Exchange By Investing.com - Investing.com South Africa
Oncolytics Biotech to delist from Toronto Stock Exchange - Investing.com
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep - PR Newswire
Oncolytics Biotech Inc. shares fall 1.94% after-hours as stock futures rise and trade negotiations continue. - AInvest
Oncolytics Biotech Inc. shares rise 3.16% premarket as stock futures rise ahead of tariff deadline. - AInvest
Oncolytics Biotech to Hold Virtual Annual Meeting and Announce Q2 Financial Results - TipRanks
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results - Barchart.com
Oncolytics Biotech Inc. stock momentum explainedRisk/Reward Optimization Entry Point Analysis - Newser
Published on: 2025-08-04 08:21:46 - Jammu Links News
Objective long/short (ONC) Report (ONC:CA) - news.stocktradersdaily.com
What are the latest earnings results for Oncolytics Biotech Inc.Build a diversified portfolio for steady growth - Jammu Links News
What analysts say about Oncolytics Biotech Inc. stockUnbelievable profit margins - Jammu Links News
How many analysts rate Oncolytics Biotech Inc. as a “Buy”Exceptional gains - Jammu Links News
What drives Oncolytics Biotech Inc. stock priceOutstanding growth strategies - Jammu Links News
Does Oncolytics Biotech Inc. stock perform well during market downturnsGet timely market insights for better trades - Jammu Links News
When is Oncolytics Biotech Inc. stock expected to show significant growthInvest smarter with expert stock picks - Jammu Links News
What is the risk reward ratio of investing in Oncolytics Biotech Inc. stockBuild wealth with professional market analysis - Jammu Links News
Should I hold or sell Oncolytics Biotech Inc. stock in 2025Unlock powerful trading signals for profits - Jammu Links News
Why is Oncolytics Biotech Inc. stock attracting strong analyst attentionCapitalize on stocks with high profit margins - Jammu Links News
What institutional investors are buying Oncolytics Biotech Inc. stockUnlock expert insights for smarter investing - Jammu Links News
Is it the right time to buy Oncolytics Biotech Inc. stockAchieve rapid financial growth with expert help - Jammu Links News
Is Oncolytics Biotech Inc. a growth stock or a value stockInvest smarter with real-time trading signals - Jammu Links News
What catalysts could drive Oncolytics Biotech Inc. stock higher in 2025Invest smarter with expert stock recommendations - Jammu Links News
What are analysts’ price targets for Oncolytics Biotech Inc. in the next 12 monthsLow Risk Recommendation With High Returns - Jammu Links News
(ONC) Financial Trading Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech Engages FDA for Pivotal Pancreatic Cancer Study - The Globe and Mail
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - BioSpace
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - PR Newswire
What’s the recovery path for long term holders of Oncolytics Biotech Inc.High Conviction Intraday Stock Signals Detected - metal.it
Survival Data and Regulatory Greenlights Fuel Momentum in Immunotherapy Stocks - Baystreet.ca
Oncolytics Biotech to engage FDA on potential pancreatic cancer study By Investing.com - Investing.com Nigeria
Oncolytics Biotech to engage FDA on potential pancreatic cancer study - Investing.com
Bollinger Bands Expand on Oncolytics Biotech Inc. — Volatility AheadRisk Controlled Picks With Real Returns Outlined - metal.it
Oncolytics Biotech sparks FDA discussions for potential pivotal pancreatic cancer trial | 2025-07-29 | Investing News - Stockhouse
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Published on: 2025-07-29 15:02:09 - metal.it
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):